{
    "root": "d6b874c5-c383-4b28-8be1-2098e4d4fd0a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250520",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "METHACRYLIC ACID",
            "code": "1CS02G8656"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": "Divalproex sodium delayed-release capsules are an anti-epileptic drug indicated for: • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1)",
    "contraindications": "• Divalproex sodium delayed-release capsules may be swallowed whole or the contents may be sprinkled on soft food. The drug/food mixture should be swallowed immediately (avoid chewing) (2.2) • Safety of doses above 60 mg/kg/day is not established (2.1 , 2.2) • Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy (2.1) • Absence Seizures: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects (2.1)",
    "warningsAndPrecautions": "Divalproex Sodium Delayed-Release Capsules, USP equivalent to 125 mg of valproic acid are white to off-white free flowing pellets filled in size '0' hard gelatin capsules with blue colored cap printed with \"ZA66\" in black ink and white body printed with \"125mg\" in black ink and are supplied as follows:   \n                  Overbagged with 10 delayed-release capsules per bag, NDC 55154-4759-0\n                  WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                  \n                     Storage:\n                      Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].  \n                  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.",
    "adverseReactions": "•Divalproex sodium delayed-release capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction     [see      Warnings and Precautions (5.1)].     \n                     \n                     \n                        •Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder     [see      Warnings and Precautions (5.1)].     \n                     \n                     \n                        •Divalproex sodium delayed-release capsules are contraindicated in patients with known hypersensitivity to the drug     [see      Warnings and Precautions (5.12)].     \n                     \n                     \n                        •Divalproex sodium delayed-release capsules are contraindicated in patients with known urea cycle disorders     [see      Warnings and Precautions (5.6)].     \n                     \n                     \n                        •For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release capsules are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception     [see      Warnings and Precautions (5.2,      5.3,      5.4) and      Use in Specific Populations (8.1)]."
}